The role of interferon in cancer therapy: A current perspective

@article{Goldstein1988TheRO,
  title={The role of interferon in cancer therapy: A current perspective},
  author={David Goldstein and John Laszlo},
  journal={CA: A Cancer Journal for Clinicians},
  year={1988},
  volume={38}
}
Recombinant interferon alpha has now been established as having a distinct if narrow role when used as a single agent in cancer therapy. The responses to single-agent therapy can be grouped as shown in Table 7. Interferon is likely to be the treatment of choice for hairy cell leukemia and possibly also for symptomatic nodular lymphoma. Interferon is very useful in treating papillomas and condylomas, and its role as a local agent will probably expand. The list of responding cancers for alpha… Expand
The role of interferon-alpha in the treatment of chronic myeloid leukemia.
TLDR
There is both clinical and laboratory evidence suggesting imatinib therapy alone is not curative in CML, whereas IFN has induced a low but reproducible curative effect in some patients, which may be the basis for the reincorporation of IFN into the management of CML. Expand
Is there a role for interferon in the treatment of small cell lung cancer
Introduction The term interferon (IFN) was first coined by Isaacs and Lindemann in 1957 to signify a substance elaborated by virally all infected cells that functions to inhibit viral replication [Expand
Cytokines in the Treatment of Cancer.
  • K. Conlon, M. Miljkovic, T. Waldmann
  • Biology, Medicine
  • Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • 2019
TLDR
Current knowledge and clinical application of cytokines either as monotherapy or in combination with other biological agents are summarized and a discussion of future directions for research on these cytokines is emphasized to bring them to fruition as major contributors for the treatment of metastatic malignancy. Expand
New therapeutic modalities for cancer.
A review is given on new biological approaches to cancer therapy based on knowledge concerning interferons, interleukins. LAK-cells, tumour-infiltrating lymphocytes, tumour necrosis factor,Expand
Adjunctive interferon-α-2c in stage IIIb/Iv small-cell lung cancer : a phase III trial
TLDR
Patients in the IFN arm had higher rates of complete and partial remission and a lower rate of progressive disease in the interferon arm than those who received chemotherapy alone after the induction phase. Expand
Interferon. Coming of age.
TLDR
In this issue of theArchives, Edwards and coworkers demonstrate the antitumor effect of interferon alfa-2b in a sustained release formulation for the treatment of basal cell carcinomas. Expand
IFN-λ cancer immunotherapy: new kid on the block.
TLDR
IFN-λ offers unique advantages, including a more tumor cell selective targeting, lower off-target binding and an ability to generate both innate and adaptive immune responses, according to a review of the current landscape of IFN-α use in oncology. Expand
Interferons in oral potentially malignant disorders, its effect and cure: A review
TLDR
This review will demonstrate the critical importance IFNs and its mode of action with a translational approach toward advancing the understanding of the pathobiologic basis of tumorigenesis and therapeutic outcome of IFNs in oral potentially malignant disorders. Expand
Cytokines in the Treatment of Melanoma
TLDR
The basic biology of cytokines involved in the treatment of melanoma and their therapeutic applications are reviewed and several innovative technological approaches that have been developed to improve the pharmacokinetics, safety, and efficacy of these cytokines are described. Expand
Phase I Clinical Trial of Interleukin 2 and α-Interferon: Toxicity and Immunologic Effects
TLDR
Three partial responses and one minor response were observed in patients with malignant melanoma, renal cell carcinoma, and breast cancer, and immunological studies suggested that natural killer activity was related to both the dose of rIL-2 and the doses of rHuIFN-alpha 2a. Expand
...
1
2
3
4
5
...